1.Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J et al: Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes care 2016, 39(7):1186–1201.
2.Vinicor F, Bowman B: The metabolic syndrome: the emperor needs some consistent clothes. Diabetes care 2004, 27(5):1243; author reply 1244.
3.Marott SC, Nordestgaard BG, Tybjaerg-Hansen A, Benn M: Components of the Metabolic Syndrome and Risk of Type 2 Diabetes. The Journal of clinical endocrinology and metabolism 2016, 101(8):3212–3221.
4.Nolan CJ, Ruderman NB, Kahn SE, Pedersen O, Prentki M: Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes 2015, 64(3):673–686.
5.Goldberg IJ, Merkel M: Lipoprotein lipase: physiology, biochemistry, and molecular biology. Frontiers in bioscience: a journal and virtual library 2001, 6:D388–405.
6.Hu Y, Liu W, Huang R, Zhang X: A systematic review and meta-analysis of the relationship between lipoprotein lipase Asn291Ser variant and diseases. Journal of lipid research 2006, 47(9):1908–1914.
7.Li YX, Han TT, Liu Y, Zheng S, Zhang Y, Liu W, Hu YM: Insulin resistance caused by lipotoxicity is related to oxidative stress and endoplasmic reticulum stress in LPL gene knockout heterozygous mice. Atherosclerosis 2015, 239(1):276–282.
8.Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P et al: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (London, England) 2005, 366(9500):1849–1861.
9.Chan SM, Zeng XY, Sun RQ, Jo E, Zhou X, Wang H, Li S, Xu A, Watt MJ, Ye JM: Fenofibrate insulates diacylglycerol in lipid droplet/ER and preserves insulin signaling transduction in the liver of high fat fed mice. Biochimica et biophysica acta 2015, 1852(7):1511–1519.
10.Chan SM, Sun RQ, Zeng XY, Choong ZH, Wang H, Watt MJ, Ye JM: Activation of PPARalpha ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Diabetes 2013, 62(6):2095–2105.
11.Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412–419.
12.Holzl B, Paulweber B, Sandhofer F, Patsch JR: Hypertriglyceridemia and insulin resistance. Journal of internal medicine 1998, 243(1):79–82.
13.Mateos R, Lecumberri E, Ramos S, Goya L, Bravo L: Determination of malondialdehyde (MDA) by high-performance liquid chromatography in serum and liver as a biomarker for oxidative stress. Application to a rat model for hypercholesterolemia and evaluation of the effect of diets rich in phenolic antioxidants from fruits. Journal of chromatography B, Analytical technologies in the biomedical and life sciences 2005, 827(1):76–82.
14.Szalat A, Durst R, Leitersdorf E: Managing dyslipidaemia in type 2 diabetes mellitus. Best practice & research Clinical endocrinology & metabolism 2016, 30(3):431–444.
15.Hu Y, Ren Y, Luo RZ, Mao X, Li X, Cao X, Guan L, Chen X, Li J, Long Y et al: Novel mutations of the lipoprotein lipase gene associated with hypertriglyceridemia in members of type 2 diabetic pedigrees. Journal of lipid research 2007, 48(8):1681–1688.
16.McKeage K, Keating GM: Fenofibrate: a review of its use in dyslipidaemia. Drugs 2011, 71(14):1917–1946.
17.Jeong S, Yoon M: Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice. Experimental & molecular medicine 2009, 41(6):397–405.
18.Ueno H, Saitoh Y, Mizuta M, Shiiya T, Noma K, Mashiba S, Kojima S, Nakazato M: Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome. Obesity research & clinical practice 2011, 5(4):e267–360.
19.Su J, Zhou L, Kong X, Yang X, Xiang X, Zhang Y, Li X, Sun L: Endoplasmic reticulum is at the crossroads of autophagy, inflammation, and apoptosis signaling pathways and participates in the pathogenesis of diabetes mellitus. Journal of diabetes research 2013, 2013:193461.
20.Zhang N, Lu Y, Shen X, Bao Y, Cheng J, Chen L, Li B, Zhang Q: Fenofibrate treatment attenuated chronic endoplasmic reticulum stress in the liver of nonalcoholic fatty liver disease mice. Pharmacology 2015, 95(3–4):173–180.
21.Yan F, Wang Q, Xu C, Cao M, Zhou X, Wang T, Yu C, Jing F, Chen W, Gao L et al: Peroxisome proliferator-activated receptor alpha activation induces hepatic steatosis, suggesting an adverse effect. PloS one 2014, 9(6):e99245.
22.Samocha-Bonet D, Heilbronn LK, Lichtenberg D, Campbell LV: Does skeletal muscle oxidative stress initiate insulin resistance in genetically predisposed individuals? Trends in endocrinology and metabolism 2010, 21(2):83–88.
23.Houstis N, Rosen ED, Lander ES: Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440(7086):944–948.
24.Rani V, Deep G, Singh RK, Palle K, Yadav UC: Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Life Sci 2016, 148:183–193.
25.Meng R, Zhu DL, Bi Y, Yang DH, Wang YP: Anti-oxidative effect of apocynin on insulin resistance in high-fat diet mice. Annals of clinical and laboratory science 2011, 41(3):236–243.
26.Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E et al: Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet (London, England) 2007, 370(9600):1687–1697.
27.Bordet R, Ouk T, Petrault O, Gele P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC et al: PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochemical Society transactions 2006, 34(Pt 6):1341–1346.
28.Shipman KE, Strange RC, Ramachandran S: Use of fibrates in the metabolic syndrome: A review. World journal of diabetes 2016, 7(5):74–88.